Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001994 · ClinicalTrials.gov registry record · NA
A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
NCT00001994: Completed NA study, sponsored by Glaxo Wellcome.
NCT00001994 is a NA study that has completed, run by Glaxo Wellcome. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001994, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To evaluate the safety and tolerance of atovaquone (566C80) in AIDS patients with central nervous system (CNS) toxoplasmosis. To evaluate the efficacy of 566C80 in the acute treatment and suppression of CNS toxoplasmosis in AIDS patients who fail or who cannot tolerate conventional therapy.
Interventions
- DRUG Atovaquone
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00001994 record still lists
NCT00001994 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Atovaquone is the first listed.
NCT00001994 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00001994 about?
NCT00001994 is a clinical study titled "A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine". To evaluate the safety and tolerance of atovaquone (566C80) in AIDS patients with central nervous system (CNS) toxoplasmosis. To evaluate the efficacy of 566C80 in the acute treatment and suppression of CNS toxoplasmosis in AIDS patients who fail or who cannot tolerate conventional therapy.
What is the current status of trial NCT00001994?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00001994?
The interventions under investigation include: Atovaquone (DRUG).
Who is sponsoring clinical trial NCT00001994?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.